A rundown of several oil companies that could soon be on the block.
This deal will certainly strengthen Chevron's position in the Permian Basin, while also adding to global reserves of both petroleum and LNG.
Anadarko is surging as its planned, $33 billion acquisition by Chevron recognizes its underlying value.
A combination of good economic news and friendly central banks creates a positive environment and leaves bears frustrated.
Wynn aborted talks to acquire Australia's largest casino operator when word of the negotiations leaked, but observers think a deal still may happen.
There is certainly too much to ignore about STZ for the majority of analysts.
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Apple's news and magazine subscription service reportedly amassed over 200,000 subscribers in its first 48 hours.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Time to break down the best bet.
How to play Disney's tumble after the close of the Fox deal.
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Does the MAR have too many brands? 'Absolutely not,' says CEO Sorenson.
With Nvidia's needs addressed, the stock is set to surge.
Consolidation is driving growth in the semis, but tech-led strength is never a bad thing.
It signals the glut in chips may be done with, which is good news for most of the semiconductor names.
Let's see if the charts are desirable.
Let's see what the charts and indicators look like.
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
If we can advance without China then who the heck knows where we can go with it.
Cash is a lazy asset, but the genesis of Berkshire's underperformance has been choosing the wrong investments.
Just because the stock is still down substantially from its all-time highs doesn't mean that it is still 'cheap'.
The question for us though becomes is this, or when is, the right time for investors to create some value for themselves?
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Shares of food giant are cratering as faith in management fades.
Is CVS open to those seeking value?
Pharmacy Benefit Managers (PBMs) are in for some problems if proposed regulation is given approval.
CVS is losing value for investors.
I still believe it will be a big year for buyouts across the biotech industry.
Analysts need to recognize this shift in the banking markets.